

--35. (Amended) A method of identifying an agent which modulates the expression of a nucleic acid encoding a protein of claim 31, comprising:

exposing cells which express the nucleic acid to the agent; and

determining whether the agent modulates expression of said nucleic acid, thereby identifying an agent which modulates the expression of a nucleic acid encoding the protein.

A
W
--36. (Amended) A method of identifying an agent which modulates at least one activity of a protein of claim 31, comprising:

exposing cells which express the protein to the agent;

determining whether the agent modulates at least one activity of said protein, thereby identifying an agent which modulates at least one activity of the protein.--

A
S
--38. (Amended) A method of identifying binding partners for a protein of claim 31, comprising:

exposing said protein to a potential binding partner; and

determining if the potential binding partner binds to said protein, thereby identifying binding partners for the protein.

A
S
--39. (Amended) A method of modulating the expression of a nucleic acid encoding a protein of claim 31, comprising:

administering an effective amount of an agent which modulates the expression of a nucleic acid encoding the protein.

40. (Amended) A method of modulating at least one activity of a protein of claim 31, comprising:

administering an effective amount of an agent which modulates at least one activity of the protein.

41. (Amended) A non-human transgenic animal modified to contain the nucleic acid molecule of claim 1.--

A
A
--43. (Amended) A method of diagnosing a disease state in a subject, comprising determining the level of expression of a nucleic acid molecule of claim 1.--

--49. (Amended) A composition comprising an isolated nucleic acid molecule of claim 1 and an aqueous carrier.

A
50. (Amended) A method for the treatment or prevention of a disease state in a subject, comprising administering to said subject an effective amount of a nucleic acid molecule of claim 1 or an agonist or antagonist thereof, thereby effecting said treatment or prevention of a disease state in said subject.--

AS
--58. (Amended) The computer system of claim 56, wherein the database further comprises sequence information for said at least one nucleic acid sequence.

AS
59. (Amended) The computer system of claim 56, wherein the database further comprises information identifying the expression level for said at least one nucleic acid sequence in at least one normal mast cell.

60. (Amended) A computer system of claim 56, wherein the database further comprises information identifying the expression level of said at least one nucleic acid sequence in at least one mast cell from a patient with allergic hypersensitivity.--

Ag
--62. (Amended) A computer system of claim 56, further comprising records including descriptive information from an external database, which information correlates said genes to records in the external database.--

Ano
--66. (Amended) A method of claim 64, wherein the expression level of at least two nucleic acid sequences are compared.--

ATI
/ /
Please add the following new claims:

--70.(New) A method of diagnosing a disease state in a subject, comprising determining the level of expression of a protein of claim 31.

71.(New) A method for the treatment or prevention of a disease state in a subject, comprising administering to said subject an effective amount of a protein of claim 31 or an